Clinic & Chair of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Dębinki 7, 80-211, Gdańsk, Poland.
Department of Clinical Chemistry, Medical University of Gdańsk, Dębinki 7, 80-211, Gdańsk, Poland.
Lipids Health Dis. 2019 Mar 9;18(1):60. doi: 10.1186/s12944-019-1003-x.
Chronic kidney disease (CKD) associates with complex lipoprotein disturbances resulting in high cardiovascular risk. Apolipoprotein E (APOE) is a polymorphic protein with three common isoforms (E2; E3; E4) that plays a crucial role in lipoprotein metabolism, including hepatic clearance of chylomicrons and very low-density lipoprotein (VLDL) remnants, and reverse cholesterol transport. It demonstrates anti-atherogenic properties but data concerning the link between polymorphism and level of APOE in CKD patients are inconclusive. The aim of our research was to assess the relationship between APOE gene polymorphism and APOE concentration and its redistribution among lipoproteins along with CKD progression.
90 non-dialysed CKD patients were included into the study. Real time PCR was used for APOE genotyping. APOE level was measured in serum and in isolated lipoprotein fractions (VLDL; IDL + HDL; HDL). Kidney function was assessed using eGFR CKD-EPI formula.
The population was divided into three APOE genotype subgroups: E2(ε2ε3), E3(ε3ε3) and E4(ε3ε4). The highest APOE level was observed for the E2 subgroup (p < 0.001). APOE concentration positively correlated with eGFR value in the E2 subgroup (r = 0.7, p < 0.001) but inversely in the E3 subgroup (r = - 0.29, p = 0.02).). A lower concentration of APOE in the E2 subgroup was associated with its diminished contents in HDL and IDL + LDL particles. In the E3 subgroup, the higher concentration of APOE was related to the increased number of non-HDL lipoproteins.
In patients with CKD, APOE genotype as well as renal function are associated with the concentration of APOE and its redistribution among lipoprotein classes.
慢性肾脏病（CKD）与复杂的脂蛋白紊乱有关，导致心血管风险增加。载脂蛋白 E（APOE）是一种具有三种常见同工型（E2；E3；E4）的多态蛋白，在脂蛋白代谢中起着至关重要的作用，包括乳糜微粒和极低密度脂蛋白（VLDL）残粒的肝脏清除以及胆固醇逆转运。它具有抗动脉粥样硬化的特性，但关于 CKD 患者中 APOE 多态性与 APOE 水平之间的关系的数据尚无定论。我们的研究目的是评估 APOE 基因多态性与 APOE 浓度及其在脂蛋白中的重新分布与 CKD 进展之间的关系。
纳入 90 名未接受透析的 CKD 患者进行研究。使用实时 PCR 进行 APOE 基因分型。在血清和分离的脂蛋白级分（VLDL；IDL+HDL；HDL）中测量 APOE 水平。使用 eGFR CKD-EPI 公式评估肾功能。
人群分为三个 APOE 基因型亚组：E2（ε2ε3）、E3（ε3ε3）和 E4（ε3ε4）。E2 亚组的 APOE 水平最高（p<0.001）。APOE 浓度与 E2 亚组的 eGFR 值呈正相关（r=0.7，p<0.001），但与 E3 亚组呈负相关（r=-0.29，p=0.02）。E2 亚组中 APOE 浓度较低与其在 HDL 和 IDL+LDL 颗粒中的含量减少有关。在 E3 亚组中，APOE 浓度较高与非 HDL 脂蛋白数量增加有关。
在 CKD 患者中，APOE 基因型以及肾功能与 APOE 浓度及其在脂蛋白类别中的重新分布有关。
